23.8  -0.385 (-1.59%)		09-11 16:00
Open: 24.75 High: 24.765 Volume: 5,450,580		Pre. Close: 24.185 Low: 23.66 Market Cap: 12,305(M)

Short term
Mid term
Targets	6-month :	30.77	1-year :	32.71
Resists	First :	26.34	Second :	28
Pivot price	25.56
Supports	First :	23.65	Second :	19.68
MAs	MA(5) :	24.61	MA(20) :	25.75
	MA(100) :	21.95	MA(250) :	20.61
MACD	MACD :	-0.3	Signal :	0.1
%K %D	K(14,3) :	4.5	D(3) :	9.2
RSI	RSI(14): 35.1
52-week	High :	29.98	Low :	15.71

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ BAX ] has closed below the lower bollinger band by 2.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 0.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	24.8 - 24.98	24.98 - 25.11
Low:	23.22 - 23.45	23.45 - 23.62
Close:	23.48 - 23.79	23.79 - 24.03

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Sat, 12 Sep 2026
Baxter International Inc Share Price - BAX, RNS News, Articles, Quotes, & Charts (NYSE:BAX) - Proactive financial news

Tue, 08 Sep 2026
A Look at Baxter International Inc (BAX) After 3.8% Decline -- G - GuruFocus

Mon, 07 Sep 2026
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure - finance.yahoo.com

Mon, 07 Sep 2026
Baxter International Inc. (BAX) Stock Analysis: Exploring Potential Upside and Analyst Ratings - DirectorsTalk Interviews

Fri, 04 Sep 2026
BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract - Eastern Progress

Thu, 03 Sep 2026
Baxter (NYSE: BAX) exec ends with 29,164 shares after tax move - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	517 (M)
Shares Float	514 (M)
Held by Insiders	0.3 (%)
Held by Institutions	110.2 (%)
Shares Short	23,910 (K)
Shares Short P.Month	36,840 (K)

EPS	-1.88
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	12
Profit Margin	-9.3 %
Operating Margin	14.4 %
Return on Assets (ttm)	2.8 %
Return on Equity (ttm)	-14.4 %
Qtrly Rev. Growth	5.3 %
Gross Profit (p.s.)	7.56
Sales Per Share	22.18
EBITDA (p.s.)	3.63
Qtrly Earnings Growth	36.7 %
Operating Cash Flow	1,320 (M)
Levered Free Cash Flow	1,000 (M)

PE Ratio	-12.66
PEG Ratio	36.6
Price to Book value	1.98
Price to Sales	1.07
Price to Cash Flow	9.32

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.